PureTech Health PLC PRTC Presents Data for LYT-210 IO Program at AACR
April 12 2021 - 7:00AM
RNS Non-Regulatory
TIDMPRTC
PureTech Health PLC
12 April 2021
12 April 2021
PureTech Health plc
PureTech Presents Promising Preclinical Data from LYT-210
Immuno-Oncology Program at American Association for Cancer Research
(AACR) Annual Meeting
Novel antibody demonstrates highly specific and highly potent
targeting of immunosuppressive <GAMMA> 1 T cells from cancer
patients
Enriched in many intractable solid tumors and blood of cancer
patients, <GAMMA> 1 T cells represent important new target
for cancer immunotherapy
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the
"Company"), a clinical-stage biotherapeutics company dedicated to
discovering, developing and commercializing highly differentiated
medicines for devastating diseases, today announced the
presentation of a scientific poster detailing additional promising
preclinical results for its LYT-210 antibody at the 2021 American
Association for Cancer Research (AACR) Annual Virtual Meeting.
LYT-210 is a novel, fully human monoclonal antibody (mAb)
directed against T cells bearing <GAMMA> 1 receptors, which
are known to suppress the anti-tumor immune response. The new
research shared at AACR demonstrates that LYT-210 is both highly
specific and highly potent, rapidly inducing cell death of
immune-suppressive <GAMMA> 1 T cells, while sparing other T
cells that play important roles in a healthy immune response. The
research was conducted in vitro using both patient blood and cancer
tissue. LYT-210 has potential as either a single agent or in
combination with checkpoint inhibitors and other anti-cancer
treatments.
"The role of <GAMMA> 1 T cells in cancer immune
suppression has come into sharp focus in recent years. We now know
that these cells deploy multiple immunosuppressive signals to
dampen the anti-tumor response and enable the cancer to grow and
spread," said Aleksandra Filipovic , M.D. Ph.D., Head of Oncology
at PureTech. "We are excited by these new data demonstrating that
our LYT-210 therapeutic candidate can precisely target and swiftly
deplete pathogenic <GAMMA> 1 T cells. We believe that
removing these culprits from the tumor microenvironment
systemically may have the potential to reawaken the immune system
and contribute to a strong anti-tumor response. Moreover, both we
and others in the field have established that a heightened presence
of pathogenic <GAMMA> 1 T cells in tumor tissue and blood is
correlated with more aggressive disease, poorer response to some
therapies and a lower chance of survival. Given those links, we
believe that the biomarker-centric approach we are developing as
part of our <GAMMA> 1 T cell program may have the potential
to identify and select the patients who are most likely to benefit
from LYT-210 in the clinic and beyond."
<GAMMA> 1 T cells are upregulated in multiple solid tumors
including breast cancer, glioblastoma, melanoma and pancreatic
cancer. They suppress the immune response through multiple
mechanisms, including blocking effector T cells, hindering
antigen-presenting dendritic cells, restricting the anti-tumoral
activity of <GAMMA> 2 T cells and attracting tumor-associated
macrophages and myeloid-derived suppressor cells to the tumor
microenvironment. Pathogenic <GAMMA> 1 T cells are distinct
from cytotoxic <GAMMA> T cells, which are being used for
adoptive T cell transfer or therapeutic engagement with bispecific
antibodies. Depleting pathogenic <GAMMA> 1 T cells has the
capacity to modulate both innate and adaptive immunity, and their
distinct phenotypic and functional properties make them excellent
potential therapeutic targets.
About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated
to discovering, developing and commercializing highly
differentiated medicines for devastating diseases, including
intractable cancers, lymphatic and gastrointestinal diseases,
central nervous system disorders and inflammatory and immunological
diseases, among others. The Company has created a broad and deep
pipeline through the expertise of its experienced research and
development team and its extensive network of scientists,
clinicians and industry leaders. This pipeline, which is being
advanced both internally and through PureTech's Founded Entities,
as of the date of PureTech's most recently filed Registration
Statement on Form 20-F, was comprised of 24 therapeutics and
therapeutic candidates, including two that have received FDA
clearance and European marketing authorization. All of the
underlying programs and platforms that resulted in this pipeline of
product candidates were initially identified or discovered and then
advanced by the PureTech team through key validation points based
on the Company's unique insights into the biology of the brain,
immune and gut, or BIG, systems and the interface between those
systems, referred to as the BIG Axis.
For more information, visit www.puretechhealth.com or connect
with us on Twitter @puretechh.
Cautionary Note Regarding Forward-Looking Statements
This press release contains statements that are or may be
forward-looking statements, including statements that relate to the
company's future prospects, developments, and strategies. The
forward-looking statements are based on current expectations and
are subject to known and unknown risks and uncertainties that could
cause actual results, performance and achievements to differ
materially from current expectations, including, but not limited
to, our expectations regarding the potential therapeutic benefits
of our therapeutic candidates, our expectations regarding the
potential mechanism of action and related benefits expected from
LYT-210 based on the preclinical results presented at AACR, and
those risks and uncertainties described in the risk factors
included in the regulatory filings for PureTech Health plc. These
forward-looking statements are based on assumptions regarding the
present and future business strategies of the company and the
environment in which it will operate in the future. Each
forward-looking statement speaks only as at the date of this press
release. Except as required by law and regulatory requirements,
neither the company nor any other party intends to update or revise
these forward-looking statements, whether as a result of new
information, future events or otherwise.
Contact:
Investors EU media
Allison Mead Talbot Ben Atwell, Rob Winder
+1 617 651 3156 +44 (0) 20 3727 1000
amt@puretechhealth.com ben.atwell@FTIconsulting.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAUPUPUCUPGPPB
(END) Dow Jones Newswires
April 12, 2021 07:00 ET (11:00 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jul 2023 to Jul 2024